Ahsun Riaz, Laura Kulik, Robert J. Lewandowski, Robert K. Ryu, Georgia Giakoumis Spear, Mary F. Mulcahy, Michael Abecassis, Talia Baker, Vanessa Gates, Ritu Nayar, Frank H. Miller, Kent T. Sato, Reed A. Omary, Riad Salem – 27 March 2009 – We present the correlation between radiologic and pathologic findings in HCC patients who underwent radioembolization with yttrium‐90 (90Y) microspheres prior to resection or transplantation. Thirty‐five patients with a total of 38 lesions who underwent liver explantation after 90Y radioembolization were studied.

Frank G. Schaap, Niels A. van der Gaag, Dirk J. Gouma, Peter L. M. Jansen – 27 March 2009 – Fibroblast growth factor 19 (FGF19) is an endocrine factor produced by the small intestine in response to uptake of luminal bile salts. In the liver, FGF19 binds to FGF receptor‐4, resulting in down‐regulation of cytochrome P (CYP) 7A1 and reduced bile salt synthesis.

Shuai Li, Hanjiang Fu, Yulan Wang, Yi Tie, Ruiyun Xing, Jie Zhu, Zhixian Sun, Lixin Wei, Xiaofei Zheng – 27 March 2009 – MicroRNAs (miRNAs) have recently been proposed as a versatile class of molecules involved in regulation of various biological processes. Although there is emerging evidence that some microRNAs can function as oncogenes or tumor suppressors, the specific role of miRNA in human hepatocellular carcinoma (HCC) is unclear at this point.

Sharon R. Lewin, Ruy M. Ribeiro, Anchalee Avihingsanon, Scott Bowden, Gail Matthews, Pip Marks, Stephen A. Locarnini, Kiat Ruxrungtham, Alan S. Perelson, Gregory J. Dore – 27 March 2009 – Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus‐1 (HIV‐1) and hepatitis C virus.

Dmitriy Nikitin, Linda W. Jennings, Tariq Khan, Sugam Vasani, Richard Ruiz, Edmund Q. Sanchez, Srinath Chinnakotla, Marlon F. Levy, Robert M. Goldstein, Goran B. Klintmalm – 26 March 2009 – Portal vein problems remain a formidable challenge in liver transplantation. In select situations, a portal vein conduit can provide a solution. No long‐term results have been reported.

Shin Hwang, Sung‐Gyu Lee, Chul‐Soo Ahn, Ki‐Hun Kim, Deok‐Bog Moon, Tae‐Yong Ha, Gi‐Won Song, Dong‐Hwan Jung, Je‐Ho Ryu, Kyung‐Hoon Ko, Nam‐Kyu Choi, Kwan‐Woo Kim – 26 March 2009 – This study was intended to describe in detail the surgical technique and long‐term outcome of autologous portal vein (PV) Y‐graft interposition for adult living donor liver transplantation (LDLT). We assessed the outcome of 841 patients who underwent right lobe LDLT from January 2002 to December 2007 with respect to the reconstruction of double‐graft PVs.

Joos Heisterkamp, Geert Kazemier – 26 March 2009

Marco Casaccia, Gabriele Barabino, Enzo Andorno, Maurizio Nicorelli, Elisa Porcile, Maximiliano Gelli, Pietro Diviacco, Umberto Valente – 26 March 2009

Lena Thin, Gerry MacQuillan, Leon Adams, George Garas, Cynthia Seow, Paul Cannell, Bradley Augustson, Andrew Mitchell, Luc Delriveire, Gary Jeffrey – 26 March 2009 – Acute graft‐versus‐host disease following orthotopic liver transplantation is a rare but feared complication arising in 1% to 2% of cases with a dismal prognosis. It most often presents as fever, rash, and diarrhea with or without pancytopenia. Patients die from complications of marrow failure such as sepsis or bleeding. Because of its low incidence, there is no clear treatment protocol for this complication.

Jacqueline G. O'Leary, Henry Randall, Nicholas Onaca, Linda Jennings, Göran B. Klintmalm, Gary L. Davis – 26 March 2009 – Outcomes after orthotopic liver transplantation for chronic hepatitis C have been reported to be worsening over the last 2 decades. We analyzed our center's experience over 15 years to identify trends in post–orthotopic liver transplantation survival in patients with and without hepatitis C virus infection.